AtriCure (NASDAQ:ATRC)‘s stock had its “buy” rating restated by research analysts at Piper Jaffray Companies in a research report issued to clients and investors on Sunday. They currently have a $24.00 price objective on the medical device company’s stock. Piper Jaffray Companies’ price objective would suggest a potential upside of 31.51% from the stock’s current price.

Several other research analysts also recently issued reports on ATRC. TheStreet downgraded AtriCure from a “c-” rating to a “d+” rating in a research report on Wednesday, November 29th. Zacks Investment Research downgraded AtriCure from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Canaccord Genuity cut their price target on AtriCure from $28.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. Needham & Company LLC cut their price target on AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. Finally, ValuEngine downgraded AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. AtriCure currently has a consensus rating of “Hold” and a consensus target price of $24.67.

AtriCure (NASDAQ ATRC) opened at $18.25 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.65 and a current ratio of 2.28. AtriCure has a 12-month low of $14.78 and a 12-month high of $25.18.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. The firm had revenue of $42.20 million during the quarter, compared to the consensus estimate of $43.44 million. During the same period in the previous year, the firm posted ($0.21) EPS. The company’s quarterly revenue was up 10.1% compared to the same quarter last year. sell-side analysts anticipate that AtriCure will post -0.96 earnings per share for the current fiscal year.

In related news, Director B Kristine Johnson acquired 1,500 shares of the stock in a transaction dated Wednesday, November 8th. The stock was bought at an average cost of $18.36 per share, with a total value of $27,540.00. Following the purchase, the director now directly owns 10,969 shares of the company’s stock, valued at $201,390.84. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO M. Andrew Wade sold 2,000 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $18.41, for a total transaction of $36,820.00. The disclosure for this sale can be found here. Insiders own 11.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC grew its stake in shares of AtriCure by 2.4% during the 2nd quarter. FMR LLC now owns 5,068,247 shares of the medical device company’s stock valued at $122,905,000 after buying an additional 118,247 shares during the period. Vanguard Group Inc. grew its stake in shares of AtriCure by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,446,732 shares of the medical device company’s stock valued at $35,083,000 after buying an additional 52,761 shares during the period. Victory Capital Management Inc. grew its stake in shares of AtriCure by 1.4% during the 2nd quarter. Victory Capital Management Inc. now owns 1,319,475 shares of the medical device company’s stock valued at $31,998,000 after buying an additional 18,536 shares during the period. First Light Asset Management LLC grew its stake in shares of AtriCure by 0.3% during the 2nd quarter. First Light Asset Management LLC now owns 958,858 shares of the medical device company’s stock valued at $23,252,000 after buying an additional 2,400 shares during the period. Finally, Peregrine Capital Management LLC grew its stake in shares of AtriCure by 3.5% during the 3rd quarter. Peregrine Capital Management LLC now owns 924,740 shares of the medical device company’s stock valued at $20,686,000 after buying an additional 31,526 shares during the period. 86.17% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “AtriCure (ATRC) Stock Rating Reaffirmed by Piper Jaffray Companies” was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.watchlistnews.com/atricure-atrc-stock-rating-reaffirmed-by-piper-jaffray-companies/1758368.html.

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.